Limits...
siRNA-Mediated Suppression of Synuclein γ Inhibits MDA-MB-231 Cell Migration and Proliferation by Downregulating the Phosphorylation of AKT and ERK.

He J, Xie N, Yang J, Guan H, Chen W, Wu H, Yuan Z, Wang K, Li G, Sun J, Yu L - J Breast Cancer (2014)

Bottom Line: SNCG mRNA levels were significantly reduced in MDA-MB-231 cells transfected with SNCG siRNA.Our results indicate that in SNCG siRNA-treated cells, cell migration and proliferation decreased significantly, apoptosis was induced, and the cell cycle was arrested.Western blot analysis indicated that the protein levels of p-AKT and p-ERK were much lower in the SNCG siRNA-treated groups, than in the control and NC groups.

View Article: PubMed Central - PubMed

Affiliation: Department of Breast Surgery, The First Affiliated Hospital of Shenzhen University, Second People's Hospital of Shen Zhen, Shen Zhen, China.

ABSTRACT

Purpose: Synuclein-γ (SNCG), which was initially identified as breast cancer specific gene 1, is highly expressed in advanced breast cancers, but not in normal or benign breast tissue. This study aimed to evaluate the effects of SNCG siRNA-treatment on breast cancer cells and elucidate the associated mechanisms.

Methods: Vectors containing SNCG and negative control (NC) siRNAs were transfected into MDA-MB-231 cells; mRNA levels were determined by real-time polymerase chain reaction. Cell proliferation was evaluated using the MTT assay, cell migration was assessed by the Transwell assay, apoptosis and cell cycle analyses were conducted with the flow cytometer, and Western blot analysis was performed to determine the relative levels of AKT, ERK, p-AKT, and p-ERK expression.

Results: SNCG mRNA levels were significantly reduced in MDA-MB-231 cells transfected with SNCG siRNA. Our results indicate that in SNCG siRNA-treated cells, cell migration and proliferation decreased significantly, apoptosis was induced, and the cell cycle was arrested. Western blot analysis indicated that the protein levels of p-AKT and p-ERK were much lower in the SNCG siRNA-treated groups, than in the control and NC groups.

Conclusion: SNCG siRNA could decrease the migration and proliferation of breast cancer cells by downregulating the phosphorylation of AKT and ERK.

No MeSH data available.


Related in: MedlinePlus

MTT assay at 0, 24, 48, and 72 hours after transfection. To determine the amount of cells alive, absorbance was measured on 490 nm wavelength. The cell proliferation decreased significantly in Synuclein-γ (SNCG) siRNA-1 and SNCG siRNA-2 groups (p<0.01, p<0.01) while there was no difference between negative control (NC) group and control group (p>0.05).OD=optical density.*p<0.01 vs. control group; †p<0.01 vs. NC group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4197349&req=5

Figure 3: MTT assay at 0, 24, 48, and 72 hours after transfection. To determine the amount of cells alive, absorbance was measured on 490 nm wavelength. The cell proliferation decreased significantly in Synuclein-γ (SNCG) siRNA-1 and SNCG siRNA-2 groups (p<0.01, p<0.01) while there was no difference between negative control (NC) group and control group (p>0.05).OD=optical density.*p<0.01 vs. control group; †p<0.01 vs. NC group.

Mentions: The results obtained from the MTT assay show that cell proliferation decreased significantly in the groups treated with SNCG siRNA-1 and -2 (p<0.01, p<0.01), while there were no differences between the NC and control group (p>0.05) (Figure 3). The MTT assay demonstrated that SNCG siRNAs can inhibit the proliferation of breast cancer cells.


siRNA-Mediated Suppression of Synuclein γ Inhibits MDA-MB-231 Cell Migration and Proliferation by Downregulating the Phosphorylation of AKT and ERK.

He J, Xie N, Yang J, Guan H, Chen W, Wu H, Yuan Z, Wang K, Li G, Sun J, Yu L - J Breast Cancer (2014)

MTT assay at 0, 24, 48, and 72 hours after transfection. To determine the amount of cells alive, absorbance was measured on 490 nm wavelength. The cell proliferation decreased significantly in Synuclein-γ (SNCG) siRNA-1 and SNCG siRNA-2 groups (p<0.01, p<0.01) while there was no difference between negative control (NC) group and control group (p>0.05).OD=optical density.*p<0.01 vs. control group; †p<0.01 vs. NC group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4197349&req=5

Figure 3: MTT assay at 0, 24, 48, and 72 hours after transfection. To determine the amount of cells alive, absorbance was measured on 490 nm wavelength. The cell proliferation decreased significantly in Synuclein-γ (SNCG) siRNA-1 and SNCG siRNA-2 groups (p<0.01, p<0.01) while there was no difference between negative control (NC) group and control group (p>0.05).OD=optical density.*p<0.01 vs. control group; †p<0.01 vs. NC group.
Mentions: The results obtained from the MTT assay show that cell proliferation decreased significantly in the groups treated with SNCG siRNA-1 and -2 (p<0.01, p<0.01), while there were no differences between the NC and control group (p>0.05) (Figure 3). The MTT assay demonstrated that SNCG siRNAs can inhibit the proliferation of breast cancer cells.

Bottom Line: SNCG mRNA levels were significantly reduced in MDA-MB-231 cells transfected with SNCG siRNA.Our results indicate that in SNCG siRNA-treated cells, cell migration and proliferation decreased significantly, apoptosis was induced, and the cell cycle was arrested.Western blot analysis indicated that the protein levels of p-AKT and p-ERK were much lower in the SNCG siRNA-treated groups, than in the control and NC groups.

View Article: PubMed Central - PubMed

Affiliation: Department of Breast Surgery, The First Affiliated Hospital of Shenzhen University, Second People's Hospital of Shen Zhen, Shen Zhen, China.

ABSTRACT

Purpose: Synuclein-γ (SNCG), which was initially identified as breast cancer specific gene 1, is highly expressed in advanced breast cancers, but not in normal or benign breast tissue. This study aimed to evaluate the effects of SNCG siRNA-treatment on breast cancer cells and elucidate the associated mechanisms.

Methods: Vectors containing SNCG and negative control (NC) siRNAs were transfected into MDA-MB-231 cells; mRNA levels were determined by real-time polymerase chain reaction. Cell proliferation was evaluated using the MTT assay, cell migration was assessed by the Transwell assay, apoptosis and cell cycle analyses were conducted with the flow cytometer, and Western blot analysis was performed to determine the relative levels of AKT, ERK, p-AKT, and p-ERK expression.

Results: SNCG mRNA levels were significantly reduced in MDA-MB-231 cells transfected with SNCG siRNA. Our results indicate that in SNCG siRNA-treated cells, cell migration and proliferation decreased significantly, apoptosis was induced, and the cell cycle was arrested. Western blot analysis indicated that the protein levels of p-AKT and p-ERK were much lower in the SNCG siRNA-treated groups, than in the control and NC groups.

Conclusion: SNCG siRNA could decrease the migration and proliferation of breast cancer cells by downregulating the phosphorylation of AKT and ERK.

No MeSH data available.


Related in: MedlinePlus